Table 5. Bivariate comparisons of demographic and clinical variables for 18-month survival after a lung cancer diagnosis.
(a) Ten patients were followed for less than 18 months, as they were alive at the time of data collection with a survival duration between eight and 15 months. (b) Based on separate chi-square tests for categorical variables, student’s t-test for age as a normally distributed continuous variable, and Mann-Whitney rank sums test for ECOG score as an ordinal variable. (c) PD-1: programmed cell death-1; (d) PD-L1: programmed death ligand-1; (e) COPD: chronic obstructive lung disease; (f) ECOG: Eastern Cooperative Oncology Group; (g) Gy: Gray, a unit of ionizing radiation dose in the International System of Units (SI)
| Alive at 18 Months (n = 217) | Deceased at 18 Months(a) (n = 128) | p-value (b) | |
| Type of Immunotherapy (n, %) | Neither (107, 67.3%) | Neither (52, 32.7%) | 0.24 |
| Anti-PD1 (c) (70, 60.9%) | Anti-PD1 (45, 39.1%) | ||
| Anti-PDL1 (d) (40, 56.3%) | Anti-PDL1 (31, 43.7%) | ||
| Age, years (mean ± standard deviation) | (69.0 ± 9.6) | (70.3 ± 10.3) | 0.24 |
| Gender (n, %) | Female (103, 64.0%) | Female (58, 36.0%) | 0.70 |
| Male (114, 62.0%) | Male (70, 38.0%) | ||
| Race (n, %) | Caucasian (200, 63.9%) | Caucasian (113, 36.1%) | 0.23 |
| Non-Caucasian (17, 53.1%) | Non-Caucasian (15, 46.9%) | ||
| Smoking within 5 Years of Cancer Diagnosis (n, %) | Yes (114, 59.4%) | Yes (78, 40.6%) | 0.13 |
| No (103, 67.3%) | No (50, 32.7%) | ||
| Smoking Pack-Years (n, %) | 0-10 pack-years (26, 63.4%) | 0-10 pack years (15, 36.6%) | 0.67 |
| 10-40 pack-years (86, 65.6%) | 10-40 pack years (45, 34.4%) | ||
| > 40 pack years (105, 60.7%) | > 40 pack years (68, 39.3%) | ||
| Pre-existing COPD (e) (n, %) | None, mild, or unknown (90, 56.3%) | None, mild, or unknown (70, 43.7%) | 0.02 |
| Moderate to very severe (127, 68.6%) | Moderate to very severe (58, 31.4%) | ||
| Pre-existing Emphysema (n, %) | None, mild, or unknown: 163 (62.9%) | None, mild, or unknown (96, 37.1%) | 0.98 |
| Moderate to severe (54, 62.8%) | Moderate to severe (32, 37.2%) | ||
| ECOG (f) Score (Median, range) | (1, 0 – 3) | (1, 0 – 4) | < 0.001 |
| Type of Lung Cancer (n, %) | Adenocarcinoma (88, 58.7%) | Adenocarcinoma (62, 41.3%) | 0.08 |
| Squamous cell 69 (65.1%) | Squamous cell (62, 41.3%) | ||
| Small cell (18, 52.9%) | Small cell (16, 47.1%) | ||
| Other: (41, 75.9%) | Other (13, 24.1%) | ||
| Stage of Lung Cancer (n, %) | Stage I, II, or limited 101 (71.6%) | Stage I, II, or limited (40, 28.4%) | 0.005 |
| Stage III, IV, or extensive (116, 56.9%) | Stage III, IV, or extensive (88, 43.1%) | ||
| Lung Radiation Gy (g) within 6 Months of Pneumonitis (n, %) | None (42, 68.9%) | None (19, 31.1%) | 0.45 |
| 1-30 Gy (9,64.3%) | 1-30 Gy (5, 35.7%) | ||
| 31-60 Gy (56, 57.1%) | 31-60 Gy (42, 42.9%) | ||
| > 60 Gy (4, 50.0%) | > 60 Gy (4, 50.0%) | ||
| Lung Radiation Fraction within 6 Months of Pneumonitis (n, %) | None (42, 68.9%) | None (19, 31.1%) | 0.12 |
| < 15 (19, 50.0%) | < 15 (19, 50.0%) | ||
| 15-30 (41, 57.7%) | 15-30 (30, 42.3%) | ||
| > 30 (9, 81.8%) | > 30 (2, 18.2%) | ||
| Total Lifetime Lung Radiation Gy (n, %) | < 30 (31, 52.5%) | < 30 (34, 57.6%) | 0.07 |
| > 30 (186, 65.0%) | > 30 (100, 35.0%) | ||
| Total Lifetime Lung Radiation Fraction (n, %) | < 15 (117, 64.3%) | < 15 (65, 35.7%) | 0.57 |
| > 15 (100, 61.3%) | > 15 (63, 38.7%) |